Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459149 | 0.85 | NISCH (0.41) | NPY5RKCNH2NISCHKMT2AKDM4E | |
| SCHEMBL4461990 | 0.82 | NPY5R (0.39) | NPY5RKCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL4464478 | 0.78 | NPY5R (0.36) | NPY5RKCNH2 | |
| SCHEMBL4472900 | 0.77 | NPY5R (0.58) | NPY5RNISCHALDH1A1NPC1RAB9A | |
| SCHEMBL4474683 | 0.77 | NPY5R (0.54) | NPY5RKCNH2ADRA1A | |
| Hydrochloric Acid SCHEMBL4459728 | 0.76 | NPY5R (0.56) | NPY5RNISCHALDH1A1NPC1RAB9A | |
| SCHEMBL4468774 | 0.76 | NPY5R (0.34) | NPY5RKCNH2 | |
| SCHEMBL4467622 | 0.75 | NPY5R (0.62) | NPY5RKCNH2 | |
| Hydrochloric Acid SCHEMBL4467576 | 0.75 | NPY5R (0.34) | NPY5RKCNH2 | |
| SCHEMBL4459965 | 0.74 | NPY5R (0.58) | NPY5RKCNH2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482358-B2 | Imidazoline compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-7482358-B2 | Imidazoline compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-7482358-B2 | Imidazoline compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060135559-A1 | Novel imidazoline compounds | MSD K.K. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-7064142-B2 | Imidazonline compounds | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-20030158418-A1 | Novel imidazonline compounds | MSD K.K. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135559-A1 | Novel imidazoline compounds | GPR119, NPY1R, NPY2R | NPY5R 9/4885KCNH2 473/4885NISCH 4065/4885 |
| US-20030158418-A1 | Novel imidazonline compounds | NPY1R, NPY2R, GPR119 | NPY5R 4/4885KCNH2 493/4885NISCH 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.